Novo Nordisk (NYSE:NVO) shares fell more than 5% yesterday, following comments from the President-elect regarding drug prices and a lawsuit alleging that the Danish diabetes giant made misleading earning forecasts.
The securities class action lawsuit against Nordisk also named Eli Lilly (NYSE:LLY), Sanofi (NYSE:SNY) and Merck (NYSE:MRK), claiming that Nordisk’s reported earnings and forecasts were inflated through price fixing for the company’s insulin drugs.
Get the full story at our sister site, Drug Delivery Business News.
The post Nordisk takes a hit from Trump, lawsuit appeared first on MassDevice.